{"transactions":[{"id":2045639,"issuer":{"id":7588,"kind":"organization","name":"Jasper Therapeutics, Inc."},"owners":[{"id":108538,"kind":"organization","name":"ROCHE HOLDING LTD","position":1,"cik":"0000889131","reported_name":"ROCHE HOLDING LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108539,"kind":"organization","name":"ROCHE FINANCE LTD","position":2,"cik":"0001053942","reported_name":"ROCHE FINANCE LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Voting Common Stock","published_at":"2023-01-26T17:49:09.000Z","date":"2023-01-25","kind":"sale","acquired":false,"shares":75000,"price":1.89,"value":141750.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F1","text":"Represents shares held by Roche Finance Ltd (\"Roche Finance\"). Roche Finance is a wholly owned subsidiary of Roche Holding Ltd (\"Roche Holding\"), a Swiss corporation whose shares are traded on the SIX Swiss Exchange. Roche Holding is the indirect beneficial owner of these securities of the Issuer. This Form 4 shall not be deemed an admission that any reporting person or other person is a beneficial owner of any securities of the Issuer for any purpose, other than the securities reported in this Form 4."}],"balance_after":4549606,"source":{"system":"sec-edgar","filing":"0001104659-23-007094","document":"tm234575-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/889131/000110465923007094/tm234575-1_4seq1.xml","form_type":"4"}},{"id":2525157,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":108538,"kind":"organization","name":"ROCHE HOLDING LTD","position":1,"cik":"0000889131","reported_name":"ROCHE HOLDING LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108539,"kind":"organization","name":"ROCHE FINANCE LTD","position":2,"cik":"0001053942","reported_name":"ROCHE FINANCE LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-11-04T21:45:27.000Z","date":"2021-11-02","kind":"exercise","acquired":false,"shares":318140,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for- 7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for- 7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for- 7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for- 7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held by Roche Finance Ltd (\"Roche Finance\"). Roche Finance is a wholly owned subsidiary of Roche Holding Ltd (\"Roche Holding\"), a Swiss corporation whose shares are traded on the SIX Swiss Exchange. Roche Holding is the indirect beneficial owner of these securities of the Issuer. This Form 4 shall not be deemed an admission that any reporting person or other person is a beneficial owner of any securities of the Issuer for any purpose, other than the securities reported in this Form 4."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":318140},"source":{"system":"sec-edgar","filing":"0001104659-21-134647","document":"tm2132054-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/889131/000110465921134647/tm2132054-1_4seq1.xml","form_type":"4"}},{"id":2525156,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":108538,"kind":"organization","name":"ROCHE HOLDING LTD","position":1,"cik":"0000889131","reported_name":"ROCHE HOLDING LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108539,"kind":"organization","name":"ROCHE FINANCE LTD","position":2,"cik":"0001053942","reported_name":"ROCHE FINANCE LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2021-11-04T21:45:27.000Z","date":"2021-11-02","kind":"exercise","acquired":false,"shares":2495385,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for- 7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for- 7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for- 7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for- 7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held by Roche Finance Ltd (\"Roche Finance\"). Roche Finance is a wholly owned subsidiary of Roche Holding Ltd (\"Roche Holding\"), a Swiss corporation whose shares are traded on the SIX Swiss Exchange. Roche Holding is the indirect beneficial owner of these securities of the Issuer. This Form 4 shall not be deemed an admission that any reporting person or other person is a beneficial owner of any securities of the Issuer for any purpose, other than the securities reported in this Form 4."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2495385},"source":{"system":"sec-edgar","filing":"0001104659-21-134647","document":"tm2132054-1_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/889131/000110465921134647/tm2132054-1_4seq1.xml","form_type":"4"}},{"id":2525155,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":108538,"kind":"organization","name":"ROCHE HOLDING LTD","position":1,"cik":"0000889131","reported_name":"ROCHE HOLDING LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108539,"kind":"organization","name":"ROCHE FINANCE LTD","position":2,"cik":"0001053942","reported_name":"ROCHE FINANCE LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-04T21:45:27.000Z","date":"2021-11-02","kind":"exercise","acquired":true,"shares":318140,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for- 7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held by Roche Finance Ltd (\"Roche Finance\"). Roche Finance is a wholly owned subsidiary of Roche Holding Ltd (\"Roche Holding\"), a Swiss corporation whose shares are traded on the SIX Swiss Exchange. Roche Holding is the indirect beneficial owner of these securities of the Issuer. This Form 4 shall not be deemed an admission that any reporting person or other person is a beneficial owner of any securities of the Issuer for any purpose, other than the securities reported in this Form 4."}],"balance_after":2813525,"source":{"system":"sec-edgar","filing":"0001104659-21-134647","document":"tm2132054-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/889131/000110465921134647/tm2132054-1_4seq1.xml","form_type":"4"}},{"id":2525154,"issuer":{"id":2163,"kind":"organization","name":"Entrada Therapeutics, Inc.","symbol":"TRDA"},"owners":[{"id":108538,"kind":"organization","name":"ROCHE HOLDING LTD","position":1,"cik":"0000889131","reported_name":"ROCHE HOLDING LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108539,"kind":"organization","name":"ROCHE FINANCE LTD","position":2,"cik":"0001053942","reported_name":"ROCHE FINANCE LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-11-04T21:45:27.000Z","date":"2021-11-02","kind":"exercise","acquired":true,"shares":2495385,"ownership":{"direct":false,"nature":"See Footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock and Series B Preferred Stock automatically converted into one (1) share of the Issuer's Common Stock immediately upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for- 7.235890014 reverse stock split which became effective on October 22, 2021. The Series A Preferred Stock and Series B Preferred Stock have no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Represents shares held by Roche Finance Ltd (\"Roche Finance\"). Roche Finance is a wholly owned subsidiary of Roche Holding Ltd (\"Roche Holding\"), a Swiss corporation whose shares are traded on the SIX Swiss Exchange. Roche Holding is the indirect beneficial owner of these securities of the Issuer. This Form 4 shall not be deemed an admission that any reporting person or other person is a beneficial owner of any securities of the Issuer for any purpose, other than the securities reported in this Form 4."}],"balance_after":2495385,"source":{"system":"sec-edgar","filing":"0001104659-21-134647","document":"tm2132054-1_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/889131/000110465921134647/tm2132054-1_4seq1.xml","form_type":"4"}},{"id":3077151,"issuer":{"id":11788,"kind":"organization","name":"Pandion Therapeutics, Inc.","symbol":"PAND"},"owners":[{"id":108538,"kind":"organization","name":"ROCHE HOLDING LTD","position":1,"cik":"0000889131","reported_name":"ROCHE HOLDING LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108539,"kind":"organization","name":"ROCHE FINANCE LTD","position":2,"cik":"0001053942","reported_name":"ROCHE FINANCE LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2020-07-23T16:50:15.000Z","date":"2020-07-21","kind":"exercise","acquired":false,"shares":2414098,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Roche Finance Ltd (\"Roche Finance\") is the direct beneficial owner of these securities of the Issuer. Roche Finance is a wholly owned subsidiary of Roche Holding Ltd. Roche Holding Ltd is the indirect beneficial owner of these securities of the Issuer."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":473409},"source":{"system":"sec-edgar","filing":"0000899243-20-020217","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/889131/000089924320020217/doc4.xml","form_type":"4"}},{"id":3077150,"issuer":{"id":11788,"kind":"organization","name":"Pandion Therapeutics, Inc.","symbol":"PAND"},"owners":[{"id":108538,"kind":"organization","name":"ROCHE HOLDING LTD","position":1,"cik":"0000889131","reported_name":"ROCHE HOLDING LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108539,"kind":"organization","name":"ROCHE FINANCE LTD","position":2,"cik":"0001053942","reported_name":"ROCHE FINANCE LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2020-07-23T16:50:15.000Z","date":"2020-07-21","kind":"exercise","acquired":false,"shares":13138905,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Roche Finance Ltd (\"Roche Finance\") is the direct beneficial owner of these securities of the Issuer. Roche Finance is a wholly owned subsidiary of Roche Holding Ltd. Roche Holding Ltd is the indirect beneficial owner of these securities of the Issuer."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2576564},"source":{"system":"sec-edgar","filing":"0000899243-20-020217","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/889131/000089924320020217/doc4.xml","form_type":"4"}},{"id":3077149,"issuer":{"id":11788,"kind":"organization","name":"Pandion Therapeutics, Inc.","symbol":"PAND"},"owners":[{"id":108538,"kind":"organization","name":"ROCHE HOLDING LTD","position":1,"cik":"0000889131","reported_name":"ROCHE HOLDING LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108539,"kind":"organization","name":"ROCHE FINANCE LTD","position":2,"cik":"0001053942","reported_name":"ROCHE FINANCE LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-23T16:50:15.000Z","date":"2020-07-21","kind":"purchase","acquired":true,"shares":36111,"price":18,"value":649998.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Roche Finance Ltd (\"Roche Finance\") is the direct beneficial owner of these securities of the Issuer. Roche Finance is a wholly owned subsidiary of Roche Holding Ltd. Roche Holding Ltd is the indirect beneficial owner of these securities of the Issuer."}],"balance_after":3086084,"source":{"system":"sec-edgar","filing":"0000899243-20-020217","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/889131/000089924320020217/doc4.xml","form_type":"4"}},{"id":3077148,"issuer":{"id":11788,"kind":"organization","name":"Pandion Therapeutics, Inc.","symbol":"PAND"},"owners":[{"id":108538,"kind":"organization","name":"ROCHE HOLDING LTD","position":1,"cik":"0000889131","reported_name":"ROCHE HOLDING LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108539,"kind":"organization","name":"ROCHE FINANCE LTD","position":2,"cik":"0001053942","reported_name":"ROCHE FINANCE LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2020-07-23T16:50:15.000Z","date":"2020-07-21","kind":"exercise","acquired":true,"shares":3049973,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock and Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A Preferred Stock and Series B Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F2","text":"Roche Finance Ltd (\"Roche Finance\") is the direct beneficial owner of these securities of the Issuer. Roche Finance is a wholly owned subsidiary of Roche Holding Ltd. Roche Holding Ltd is the indirect beneficial owner of these securities of the Issuer."}],"balance_after":3049973,"source":{"system":"sec-edgar","filing":"0000899243-20-020217","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/889131/000089924320020217/doc4.xml","form_type":"4"}},{"id":3855689,"issuer":{"id":164565,"kind":"organization","name":"Foundation Medicine, Inc.","symbol":"FMI"},"owners":[{"id":153046,"kind":"organization","name":"ROCHE HOLDINGS INC","position":1,"cik":"0000904566","reported_name":"ROCHE HOLDINGS INC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See footnote (1)"}},{"id":108539,"kind":"organization","name":"ROCHE FINANCE LTD","position":2,"cik":"0001053942","reported_name":"ROCHE FINANCE LTD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See footnote (1)"}},{"id":108538,"kind":"organization","name":"ROCHE HOLDING LTD","position":3,"cik":"0000889131","reported_name":"ROCHE HOLDING LTD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See footnote (1)"}}],"security":"Common Stock","published_at":"2018-08-02T19:08:21.000Z","date":"2018-07-31","kind":"purchase","acquired":true,"shares":2343078,"price":137,"value":321001686.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to the Agreement and Plan of Merger entered into between Holdings, 062018 Merger Subsidiary, Inc., a Delaware corporation and wholly owned subsidiary of Holdings (\"Purchaser\") and the Issuer, dated June 18, 2018 (the \"Merger Agreement\"), on (a) July 2, 2018, Purchaser commenced a tender offer (the \"Tender Offer\") to purchase all of the outstanding shares of Common Stock of the Issuer not already owned by Parent and its affiliates; (b) immediately after midnight on July 31, 2018, Holdings consummated the Tender Offer to purchase 13,877,949 shares of Common Stock of the Issuer; and (c) also on July 31, 2018, Purchaser merged with and into the Issuer, with the Issuer surviving (the \"Merger\")."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"This statement is being filed jointly by Roche Holdings, Inc. (\"Holdings\"), Roche Finance Ltd (\"Finance\") and Roche Holding Ltd (\"Parent\" and, together with Holdings and Finance, the \"Reporting Persons\"). Holdings is a wholly owned subsidiary of Finance, which is a wholly owned subsidiary of Parent. Additionally, the Reporting Persons understand that certain shareholders of Parent are party to a shareholder pooling agreement with respect to a significant portion of (but not a majority of) the issued shares of Parent."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Holdings is the direct beneficial owner of these shares of Common Stock of the Issuer. Finance and Parent are indirect beneficial owners of these shares of Common Stock of the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"Each Reporting Person disclaims beneficial ownership of the securities reported in Table I except to the extent of its pecuniary interest therein, if any. Each Reporting Person also disclaims beneficial ownership of any shares of Common Stock of the Issuer that may be or are beneficially owned by any other person or persons other than such Reporting Person. This Form 4 shall not be deemed an admission that any Reporting Person or other person is a beneficial owner of any shares of Common Stock of the Issuer for any purpose, other than the securities reported in Table I of this Form 4."}],"balance_after":36825315,"source":{"system":"sec-edgar","filing":"0000950103-18-009381","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/889131/000095010318009381/ownership.xml","form_type":"4"}},{"id":3855688,"issuer":{"id":164565,"kind":"organization","name":"Foundation Medicine, Inc.","symbol":"FMI"},"owners":[{"id":153046,"kind":"organization","name":"ROCHE HOLDINGS INC","position":1,"cik":"0000904566","reported_name":"ROCHE HOLDINGS INC","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See footnote (1)"}},{"id":108539,"kind":"organization","name":"ROCHE FINANCE LTD","position":2,"cik":"0001053942","reported_name":"ROCHE FINANCE LTD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See footnote (1)"}},{"id":108538,"kind":"organization","name":"ROCHE HOLDING LTD","position":3,"cik":"0000889131","reported_name":"ROCHE HOLDING LTD","relationship":{"director":true,"officer":false,"ten_percent_owner":true,"other":true,"other_text":"See footnote (1)"}}],"security":"Common Stock","published_at":"2018-08-02T19:08:21.000Z","date":"2018-07-31","kind":"purchase","acquired":true,"shares":13877949,"price":137,"value":1901279013.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"Pursuant to the Agreement and Plan of Merger entered into between Holdings, 062018 Merger Subsidiary, Inc., a Delaware corporation and wholly owned subsidiary of Holdings (\"Purchaser\") and the Issuer, dated June 18, 2018 (the \"Merger Agreement\"), on (a) July 2, 2018, Purchaser commenced a tender offer (the \"Tender Offer\") to purchase all of the outstanding shares of Common Stock of the Issuer not already owned by Parent and its affiliates; (b) immediately after midnight on July 31, 2018, Holdings consummated the Tender Offer to purchase 13,877,949 shares of Common Stock of the Issuer; and (c) also on July 31, 2018, Purchaser merged with and into the Issuer, with the Issuer surviving (the \"Merger\")."},{"field":"shares","element":"transactionShares","label":"F3","text":"Includes certain shares to be delivered pursuant to a notice of guaranteed delivery."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F1","text":"This statement is being filed jointly by Roche Holdings, Inc. (\"Holdings\"), Roche Finance Ltd (\"Finance\") and Roche Holding Ltd (\"Parent\" and, together with Holdings and Finance, the \"Reporting Persons\"). Holdings is a wholly owned subsidiary of Finance, which is a wholly owned subsidiary of Parent. Additionally, the Reporting Persons understand that certain shareholders of Parent are party to a shareholder pooling agreement with respect to a significant portion of (but not a majority of) the issued shares of Parent."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F4","text":"Holdings is the direct beneficial owner of these shares of Common Stock of the Issuer. Finance and Parent are indirect beneficial owners of these shares of Common Stock of the Issuer."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F6","text":"Each Reporting Person disclaims beneficial ownership of the securities reported in Table I except to the extent of its pecuniary interest therein, if any. Each Reporting Person also disclaims beneficial ownership of any shares of Common Stock of the Issuer that may be or are beneficially owned by any other person or persons other than such Reporting Person. This Form 4 shall not be deemed an admission that any Reporting Person or other person is a beneficial owner of any shares of Common Stock of the Issuer for any purpose, other than the securities reported in Table I of this Form 4."}],"balance_after":34482237,"source":{"system":"sec-edgar","filing":"0000950103-18-009381","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/889131/000095010318009381/ownership.xml","form_type":"4"}},{"id":3863134,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":108538,"kind":"organization","name":"ROCHE HOLDING LTD","position":1,"cik":"0000889131","reported_name":"ROCHE HOLDING LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108539,"kind":"organization","name":"ROCHE FINANCE LTD","position":2,"cik":"0001053942","reported_name":"ROCHE FINANCE LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferrred Stock","published_at":"2018-07-23T17:05:41.000Z","date":"2018-07-23","kind":"exercise","acquired":false,"shares":502632,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The Series B Preferred Stock automatically converted into Common Stock on a one-for-one basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The Series B Preferred Stock automatically converted into Common Stock on a one-for-one basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"The Series B Preferred Stock automatically converted into Common Stock on a one-for-one basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by Roche Finance Ltd (\"Roche Finance\"). Roche Finance is a wholly owned subsidiary of Roche Holding Ltd, a publicly-held corporation."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":502632},"source":{"system":"sec-edgar","filing":"0001209191-18-043630","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/889131/000120919118043630/doc4.xml","form_type":"4"}},{"id":3863133,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":108538,"kind":"organization","name":"ROCHE HOLDING LTD","position":1,"cik":"0000889131","reported_name":"ROCHE HOLDING LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108539,"kind":"organization","name":"ROCHE FINANCE LTD","position":2,"cik":"0001053942","reported_name":"ROCHE FINANCE LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferrred Stock","published_at":"2018-07-23T17:05:41.000Z","date":"2018-07-23","kind":"exercise","acquired":false,"shares":4108091,"price":0,"value":0.0,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series A Preferred Stock automatically converted into Common Stock on a one-for-one basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series A Preferred Stock automatically converted into Common Stock on a one-for-one basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series A Preferred Stock automatically converted into Common Stock on a one-for-one basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by Roche Finance Ltd (\"Roche Finance\"). Roche Finance is a wholly owned subsidiary of Roche Holding Ltd, a publicly-held corporation."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":4108091},"source":{"system":"sec-edgar","filing":"0001209191-18-043630","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/889131/000120919118043630/doc4.xml","form_type":"4"}},{"id":3863132,"issuer":{"id":79644,"kind":"organization","name":"Allakos Inc.","symbol":"ALLK"},"owners":[{"id":108538,"kind":"organization","name":"ROCHE HOLDING LTD","position":1,"cik":"0000889131","reported_name":"ROCHE HOLDING LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108539,"kind":"organization","name":"ROCHE FINANCE LTD","position":2,"cik":"0001053942","reported_name":"ROCHE FINANCE LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2018-07-23T17:05:41.000Z","date":"2018-07-23","kind":"exercise","acquired":true,"shares":4610723,"ownership":{"direct":false,"nature":"See footnote"},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series A Preferred Stock automatically converted into Common Stock on a one-for-one basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The Series B Preferred Stock automatically converted into Common Stock on a one-for-one basis immediately prior to the closing of the Issuer's initial public offering and had no expiration date."},{"field":"ownership.nature","element":"natureOfOwnership","label":"F3","text":"The shares are held of record by Roche Finance Ltd (\"Roche Finance\"). Roche Finance is a wholly owned subsidiary of Roche Holding Ltd, a publicly-held corporation."}],"balance_after":4610723,"source":{"system":"sec-edgar","filing":"0001209191-18-043630","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/889131/000120919118043630/doc4.xml","form_type":"4"}},{"id":4266050,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":108538,"kind":"organization","name":"ROCHE HOLDING LTD","position":1,"cik":"0000889131","reported_name":"ROCHE HOLDING LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108539,"kind":"organization","name":"ROCHE FINANCE LTD","position":2,"cik":"0001053942","reported_name":"ROCHE FINANCE LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series F Preferred Stock","published_at":"2017-07-05T20:27:55.000Z","date":"2017-07-05","kind":"exercise","acquired":false,"shares":989594,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Roche Finance Ltd is the direct beneficial owner of these securities of the Issuer, except for 3,870 shares of Common Stock held by Genentech, Inc., for which Roche Finance Ltd exercises voting and investment control. Roche Finance Ltd is a wholly owned subsidiary of Roche Holding Ltd. Roche Holding Ltd is the indirect beneficial owner of these securities of the Issuer. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein, if any. Each Reporting Person also disclaims beneficial ownership of any securities of the Issuer that may be or are beneficially owned by any other person or persons other than such Reporting Person. This Form 4 shall not be deemed an admission that any Reporting Person or other person is a beneficial owner of any securities of the Issuer for any purpose, other than the securities reported in this Form 4."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":99586},"source":{"system":"sec-edgar","filing":"0000899243-17-017896","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/889131/000089924317017896/doc4.xml","form_type":"4"}},{"id":4266049,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":108538,"kind":"organization","name":"ROCHE HOLDING LTD","position":1,"cik":"0000889131","reported_name":"ROCHE HOLDING LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108539,"kind":"organization","name":"ROCHE FINANCE LTD","position":2,"cik":"0001053942","reported_name":"ROCHE FINANCE LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series E-3 Preferred Stock","published_at":"2017-07-05T20:27:55.000Z","date":"2017-07-05","kind":"exercise","acquired":false,"shares":638194,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Roche Finance Ltd is the direct beneficial owner of these securities of the Issuer, except for 3,870 shares of Common Stock held by Genentech, Inc., for which Roche Finance Ltd exercises voting and investment control. Roche Finance Ltd is a wholly owned subsidiary of Roche Holding Ltd. Roche Holding Ltd is the indirect beneficial owner of these securities of the Issuer. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein, if any. Each Reporting Person also disclaims beneficial ownership of any securities of the Issuer that may be or are beneficially owned by any other person or persons other than such Reporting Person. This Form 4 shall not be deemed an admission that any Reporting Person or other person is a beneficial owner of any securities of the Issuer for any purpose, other than the securities reported in this Form 4."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":64224},"source":{"system":"sec-edgar","filing":"0000899243-17-017896","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/889131/000089924317017896/doc4.xml","form_type":"4"}},{"id":4266048,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":108538,"kind":"organization","name":"ROCHE HOLDING LTD","position":1,"cik":"0000889131","reported_name":"ROCHE HOLDING LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108539,"kind":"organization","name":"ROCHE FINANCE LTD","position":2,"cik":"0001053942","reported_name":"ROCHE FINANCE LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series E-2 Preferred Stock","published_at":"2017-07-05T20:27:55.000Z","date":"2017-07-05","kind":"exercise","acquired":false,"shares":735775,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Roche Finance Ltd is the direct beneficial owner of these securities of the Issuer, except for 3,870 shares of Common Stock held by Genentech, Inc., for which Roche Finance Ltd exercises voting and investment control. Roche Finance Ltd is a wholly owned subsidiary of Roche Holding Ltd. Roche Holding Ltd is the indirect beneficial owner of these securities of the Issuer. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein, if any. Each Reporting Person also disclaims beneficial ownership of any securities of the Issuer that may be or are beneficially owned by any other person or persons other than such Reporting Person. This Form 4 shall not be deemed an admission that any Reporting Person or other person is a beneficial owner of any securities of the Issuer for any purpose, other than the securities reported in this Form 4."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":74043},"source":{"system":"sec-edgar","filing":"0000899243-17-017896","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/889131/000089924317017896/doc4.xml","form_type":"4"}},{"id":4266047,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":108538,"kind":"organization","name":"ROCHE HOLDING LTD","position":1,"cik":"0000889131","reported_name":"ROCHE HOLDING LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108539,"kind":"organization","name":"ROCHE FINANCE LTD","position":2,"cik":"0001053942","reported_name":"ROCHE FINANCE LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series D Preferred Stock","published_at":"2017-07-05T20:27:55.000Z","date":"2017-07-05","kind":"exercise","acquired":false,"shares":3390885,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Roche Finance Ltd is the direct beneficial owner of these securities of the Issuer, except for 3,870 shares of Common Stock held by Genentech, Inc., for which Roche Finance Ltd exercises voting and investment control. Roche Finance Ltd is a wholly owned subsidiary of Roche Holding Ltd. Roche Holding Ltd is the indirect beneficial owner of these securities of the Issuer. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein, if any. Each Reporting Person also disclaims beneficial ownership of any securities of the Issuer that may be or are beneficially owned by any other person or persons other than such Reporting Person. This Form 4 shall not be deemed an admission that any Reporting Person or other person is a beneficial owner of any securities of the Issuer for any purpose, other than the securities reported in this Form 4."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":341238},"source":{"system":"sec-edgar","filing":"0000899243-17-017896","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/889131/000089924317017896/doc4.xml","form_type":"4"}},{"id":4266046,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":108538,"kind":"organization","name":"ROCHE HOLDING LTD","position":1,"cik":"0000889131","reported_name":"ROCHE HOLDING LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108539,"kind":"organization","name":"ROCHE FINANCE LTD","position":2,"cik":"0001053942","reported_name":"ROCHE FINANCE LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-07-05T20:27:55.000Z","date":"2017-07-05","kind":"purchase","acquired":true,"shares":119400,"price":15,"value":1791000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Roche Finance Ltd is the direct beneficial owner of these securities of the Issuer, except for 3,870 shares of Common Stock held by Genentech, Inc., for which Roche Finance Ltd exercises voting and investment control. Roche Finance Ltd is a wholly owned subsidiary of Roche Holding Ltd. Roche Holding Ltd is the indirect beneficial owner of these securities of the Issuer. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein, if any. Each Reporting Person also disclaims beneficial ownership of any securities of the Issuer that may be or are beneficially owned by any other person or persons other than such Reporting Person. This Form 4 shall not be deemed an admission that any Reporting Person or other person is a beneficial owner of any securities of the Issuer for any purpose, other than the securities reported in this Form 4."}],"balance_after":702363,"source":{"system":"sec-edgar","filing":"0000899243-17-017896","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/889131/000089924317017896/doc4.xml","form_type":"4"}},{"id":4266045,"issuer":{"id":7071,"kind":"organization","name":"Rein Therapeutics, Inc."},"owners":[{"id":108538,"kind":"organization","name":"ROCHE HOLDING LTD","position":1,"cik":"0000889131","reported_name":"ROCHE HOLDING LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":108539,"kind":"organization","name":"ROCHE FINANCE LTD","position":2,"cik":"0001053942","reported_name":"ROCHE FINANCE LTD","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2017-07-05T20:27:55.000Z","date":"2017-07-05","kind":"exercise","acquired":true,"shares":579093,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The Series D, Series E-2, Series E-3 and Series F Preferred Stock converted into Common Stock on a 9.937-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series D, Series E-2, Series E-3 and Series F Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial pubic offering. The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"Roche Finance Ltd is the direct beneficial owner of these securities of the Issuer, except for 3,870 shares of Common Stock held by Genentech, Inc., for which Roche Finance Ltd exercises voting and investment control. Roche Finance Ltd is a wholly owned subsidiary of Roche Holding Ltd. Roche Holding Ltd is the indirect beneficial owner of these securities of the Issuer. Each Reporting Person disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein, if any. Each Reporting Person also disclaims beneficial ownership of any securities of the Issuer that may be or are beneficially owned by any other person or persons other than such Reporting Person. This Form 4 shall not be deemed an admission that any Reporting Person or other person is a beneficial owner of any securities of the Issuer for any purpose, other than the securities reported in this Form 4."}],"balance_after":582963,"source":{"system":"sec-edgar","filing":"0000899243-17-017896","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/889131/000089924317017896/doc4.xml","form_type":"4"}}]}